Literature DB >> 28210711

Intergenically Spliced Chimeric RNAs in Cancer.

Yuemeng Jia1, Zhongqiu Xie1, Hui Li1,2.   

Abstract

Gene fusions and their encoded products (fusion RNAs and proteins) are viewed as one of the hallmarks of cancer. Traditionally, they were thought to be generated solely by chromosomal rearrangements. However, recent discoveries of trans-splicing and cis-splicing events between neighboring genes, suggest that there are other mechanisms to generate chimeric fusion RNAs without corresponding changes in DNA. In addition, chimeric RNAs have been detected in normal physiology, complicating the use of fusions in cancer detection and therapy. On the other hand, "intergenically spliced" fusion RNAs represent a new repertoire of biomarkers and therapeutic targets. Here, we review current knowledge on chimeric RNAs and implications for cancer detection and treatment, and discuss outstanding questions for the advancement of the field.

Entities:  

Keywords:  Chimeric RNA; cis-SAGe; fusion; intergenic splicing; trans-splicing

Mesh：

Substances：

Year:  2016        PMID： 28210711      PMCID： PMC5305119          DOI： 10.1016/j.trecan.2016.07.006

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  80 in total

1.  Association between sun-exposure, smoking behaviour and plasma antioxidant levels with the different manifestation of skin ageing signs between Japanese and German women--a pilot study.

Authors:  Dany Perner; Andrea Vierkötter; Dorothee Sugiri; Mary Matsui; Ulrich Ranft; Charlotte Esser; Stephane Ethève; Regina Goralczyk; Natsumi Kaneko; Ai Yamamoto; Akimichi Morita; Jean Krutmann; Ursula Krämer
Journal:  J Dermatol Sci       Date:  2011-03-05       Impact factor: 4.563

2.  Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing.

Authors:  Kalpana Kannan; Liguo Wang; Jianghua Wang; Michael M Ittmann; Wei Li; Laising Yen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-12       Impact factor: 11.205

Review 3.  Clinical cancer genomics: how soon is now?

Authors:  Barry S Taylor; Marc Ladanyi
Journal:  J Pathol       Date:  2010-10-28       Impact factor: 7.996

4.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

Authors:  Karin G Hermans; Ronald van Marion; Herman van Dekken; Guido Jenster; Wytske M van Weerden; Jan Trapman
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

5.  Targeted discovery of novel human exons by comparative genomics.

Authors:  Adam Siepel; Mark Diekhans; Brona Brejová; Laura Langton; Michael Stevens; Charles L G Comstock; Colleen Davis; Brent Ewing; Shelly Oommen; Christopher Lau; Hung-Chun Yu; Jianfeng Li; Bruce A Roe; Phil Green; Daniela S Gerhard; Gary Temple; David Haussler; Michael R Brent
Journal:  Genome Res       Date:  2007-11-07       Impact factor: 9.043

6.  TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals.

Authors:  Andrew Chase; Thomas Ernst; Andreas Fiebig; Andrew Collins; Francis Grand; Philipp Erben; Andreas Reiter; Stefan Schreiber; Nicholas C P Cross
Journal:  Haematologica       Date:  2009-10-01       Impact factor: 9.941

7.  Site-specific DICER and DROSHA RNA products control the DNA-damage response.

Authors:  Sofia Francia; Flavia Michelini; Alka Saxena; Dave Tang; Michiel de Hoon; Viviana Anelli; Marina Mione; Piero Carninci; Fabrizio d'Adda di Fagagna
Journal:  Nature       Date:  2012-08-09       Impact factor: 49.962

8.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

9.  Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.

Authors:  Ying Li; Yongwen Li; Tong Yang; Sen Wei; Jing Wang; Min Wang; Yuli Wang; Qinghua Zhou; Hongyu Liu; Jun Chen
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

10.  Recurrent chimeric fusion RNAs in non-cancer tissues and cells.

Authors:  Mihaela Babiceanu; Fujun Qin; Zhongqiu Xie; Yuemeng Jia; Kevin Lopez; Nick Janus; Loryn Facemire; Shailesh Kumar; Yuwei Pang; Yanjun Qi; Iulia M Lazar; Hui Li
Journal:  Nucleic Acids Res       Date:  2016-02-02       Impact factor: 16.971
View more
  28 in total

1.  Evidence of constraint in the 3D genome for trans-splicing in human cells.

Authors:  Cong Liu; Yiqun Zhang; Xiaoli Li; Yan Jia; Feifei Li; Jing Li; Zhihua Zhang
Journal:  Sci China Life Sci       Date:  2020-03-26       Impact factor: 6.038

Review 2.  Living Organisms Author Their Read-Write Genomes in Evolution.

Authors:  James A Shapiro
Journal:  Biology (Basel)       Date:  2017-12-06

Review 3.  RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets.

Authors:  Yang Pan; Kathryn E Kadash-Edmondson; Robert Wang; John Phillips; Song Liu; Antoni Ribas; Richard Aplenc; Owen N Witte; Yi Xing
Journal:  Trends Pharmacol Sci       Date:  2021-04       Impact factor: 14.819

Review 4.  Fusion-associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance.

Authors:  Suet Kee Loo; Megan E Yates; Sichun Yang; Steffi Oesterreich; Adrian V Lee; Xiao-Song Wang
Journal:  Genes Chromosomes Cancer       Date:  2022-02-17       Impact factor: 5.006

5.  Recurrent fusion RNA DUS4L-BCAP29 in non-cancer human tissues and cells.

Authors:  Yue Tang; Fujun Qin; Aiqun Liu; Hui Li
Journal:  Oncotarget       Date:  2017-05-09

6.  New chimeric RNAs in acute myeloid leukemia.

Authors:  Florence Rufflé; Jerome Audoux; Anthony Boureux; Sacha Beaumeunier; Jean-Baptiste Gaillard; Elias Bou Samra; Andre Megarbane; Bruno Cassinat; Christine Chomienne; Ronnie Alves; Sebastien Riquier; Nicolas Gilbert; Jean-Marc Lemaitre; Delphine Bacq-Daian; Anne Laure Bougé; Nicolas Philippe; Therese Commes
Journal:  F1000Res       Date:  2017-08-02

7.  Dysregulation of cancer genes by recurrent intergenic fusions.

Authors:  Jae Won Yun; Lixing Yang; Hye-Young Park; Chang-Woo Lee; Hongui Cha; Hyun-Tae Shin; Ka-Won Noh; Yoon-La Choi; Woong-Yang Park; Peter J Park
Journal:  Genome Biol       Date:  2020-07-06       Impact factor: 13.583

Review 8.  Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy.

Authors:  Neetha Nanoth Vellichirammal; Nagendra K Chaturvedi; Shantaram S Joshi; Donald W Coulter; Chittibabu Guda
Journal:  Cancer Lett       Date:  2020-11-25       Impact factor: 9.756

Review 9.  Transcriptional-Readthrough RNAs Reflect the Phenomenon of "A Gene Contains Gene(s)" or "Gene(s) within a Gene" in the Human Genome, and Thus Are Not Chimeric RNAs.

Authors:  Yan He; Chengfu Yuan; Lichan Chen; Mingjuan Lei; Lucas Zellmer; Hai Huang; Dezhong Joshua Liao
Journal:  Genes (Basel)       Date:  2018-01-16       Impact factor: 4.096

10.  Identification of KANSARL as the first cancer predisposition fusion gene specific to the population of European ancestry origin.

Authors:  Jeff Xiwu Zhou; Xiaoyan Yang; Shunbin Ning; Ling Wang; Kesheng Wang; Yanbin Zhang; Fenghua Yuan; Fengli Li; David D Zhuo; Liren Tang; Degen Zhuo
Journal:  Oncotarget       Date:  2017-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.